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Abstract
Background—Recipients of ABO incompatible (ABOi) living donor kidney transplants often
undergo more intense immunosuppression than their ABO compatible (ABOc) counterparts. It is
unknown if this difference leads to higher cancer risk after transplantation. Single-center studies
are too small, and lack adequate duration of follow-up, to answer this question.
Methods—We identified 318 ABOi recipients in the Cancer Transplant Match Study, a national
linkage between the Scientific Registry of Transplant Recipients and population-based U.S. cancer
registries. Seven cancers (non-Hodgkin lymphoma, Merkel cell carcinoma, gastric
adenocarcinoma, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and testicular
cancer) were identified among ABOi recipients. We then matched ABOi recipients to ABOc
controls by age, gender, race, HLA mismatch, retransplantation, and transplant year.
Results—There was no demonstrable association between ABOi and cancer in unadjusted
incidence rate ratio (IRR 0.83, 95% CI 0.33–1.71, p=0.3) or matched control analysis (IRR 0.99,
95% CI 0.38–2.23, p=0.5).
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Conclusion—To the extent that could be determined in this registry study, current
desensitization protocols are not associated with increased risk of cancer after transplantation.
Keywords
incompatible transplantation; cancer; living donor kidney transplantation
Introduction
ABO incompatible (ABOi) living donor kidney transplantation is becoming increasingly
common, largely as a response to continuing shortage of kidney donors. Since 2006, ABOi
transplants comprise 1.5% of all living donor transplants in the United States [1]. In most
reports, ABOi recipients have similar patient and graft survival to their ABO compatible
(ABOc) counterparts [1–4]. In order to achieve these results, most ABOi kidney recipients
undergo more intense immunomodulatory protocols that include plasmapheresis,
intravenous immune globulin, anti-CD20 treatment, and/or splenectomy [5, 6].
In general, the cancer risk for organ recipients is increased, due largely to
immunosuppression [7]. This increased risk is particularly pronounced among infection-
related cancers and ranges from 1.5-fold increased risk for stomach cancer to 61-fold
increased risk for Kaposi sarcoma. Individual steps of ABOi protocols, including
splenectomy and other forms of B-cell modulation, are associated with mildly increased
cancer risk in other contexts [8–10]. It is possible that these protocols might further increase
the risk of cancer after transplantation, although this has never been studied.
As ABOi transplantation becomes more common and survival improves, it is necessary to
evaluate the risks of long-term complications such as cancer in order to tailor patient
selection, consent, screening, and prevention appropriately. Our objective was to compare
cancer risk in equivalent ABOi versus ABOc living donor kidney transplant recipients using
the Transplant Cancer Match (TCM) Study, a linkage between the Scientific Registry of
Transplant Recipients (SRTR) and U.S. population-based cancer registries [7]. The TCM
offers the first opportunity to study high quality cancer follow-up data in a large, national
cohort of ABOi recipients.
Results
Comparing 318 living donor ABOi kidney recipients with 37,643 ABOc recipients during
the study period, age at transplantation, gender, race, percentage of retransplants and zero
HLA mismatch status were similar. However, a higher percentage of ABOi recipients were
African-American (19.3% vs. 14.0%, p=0.02) and had received a retransplant (11.0% vs.
8.0%, p=0.03) (Table 1).
As expected, ABOi transplantation was skewed towards more recent years, with 55.4% of
ABOi transplants performed between 2004 and 2008. The total time at risk for ABOi
recipients was 990.7 person years (median 2.00 years). An A donor to 0 recipient was the
most common type of ABOi (27.0%) (Table 2).
Among ABOi recipients, there were seven cancers identified with one case each of non-
Hodgkin lymphoma (NHL), Merkel cell carcinoma (MCC), gastric adenocarcinoma,
hepatocellular carcinoma, papillary thyroid cancer, pancreatic cancer, and testicular
germinoma. Four of these cancers were infection-related (NHL, Merkel cell carcinoma,
gastric adenocarcinoma, hepatocellular carcinoma). The time to cancer diagnosis ranged
from 0.9 to 9.2 years (median 3.6 years). ABOi recipients had no demonstrable difference in
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overall cancer risk compared to ABOc recipients in unadjusted (IRR 0.83, 95% CI 0.33–
1.71, p=0.3) or matched (IRR 0.99, 95% CI 0.38–2.23) analysis (Table 3).
The NHL case diagnosed among the ABOi recipients was a nodal Burkitt lymphoma. The
time to diagnosis was 5.9 years. ABOi recipients had no demonstrable difference in NHL
risk compared to ABOc recipients in unadjusted (IRR 0.86, 95% CI 0.02–4.85, p=0.5) or
matched (IRR 1.02, 95% CI 0.02–8.38, p=0.5) analysis.
Discussion
In this first, limited exploration of cancer after ABOi transplantation, using a national
linkage of transplant registry to cancer registry data, we did not detect an elevated post-
transplant cancer risk associated with ABO incompatibility.
Only one ABOi recipient was diagnosed with NHL, typically the most common malignancy
after transplantation (except for basal and squamous cell skin cancers). There was not a
demonstrable difference between the incidence rate of NHL in ABOi and ABOc recipients.
The single case of NHL was diagnosed at 5.9 years, consistent with the late peak of NHL
risk after transplantation [11]. While in general, late NHL is less likely to be Epstein-Barr
virus associated and more likely to be extra-nodal [12], the NHL diagnosed among the
ABOi recipients was Burkitt lymphoma and nodal. Burkitt lymphoma risk is increased in
association with immunosuppression due to HIV infection or transplantation, and possibly
related to EBV infection [13–15]. Somewhat surprisingly, there were no diagnoses of early
NHL (within 2 years after transplant) among ABOi recipients. Anti-CD20 antibodies are
given as part of incompatible desensitization protocols at certain centers and are also used in
the treatment of NHL [16, 17]. Anti-CD20 antibodies deplete B-cells that may contribute to
development of NHL. The peak period of B-cell immunomodulation with anti-CD20 is
during the peak of early risk for NHL [18]. It is possible that the anti-CD20 antibodies could
decrease risk of NHL, particularly during this early period. More targeted research into the
associations of this immunomodulation and NHL risk should be performed.
Of interest, Merkel cell carcinoma, a rare neuroendocrine tumor of the skin associated with
immunosuppressed states and thought to be caused by Merkel cell polyoma virus [19], was
diagnosed among the ABOi cohort. Merkel cell carcinoma risk is elevated among transplant
recipients [20, 21]. Increased risk has also been found in HIV-positive patients [22] and
associated with chronic lymphocytic leukemia (CLL) [23, 24]. Prominent immune
dysfunctions in CLL include B-cell dysfunction and hypogammaglobulinemia [25–27]. B-
cell deficits are also induced in ABOi recipients as part of desensitization protocols and may
offer a mechanistic explanation for the development of this rare cancer.
Strengths of our study include the use of a national cohort of living donor kidney recipients
and accurate cancer ascertainment independent of transplant center follow-up and reporting.
Using cancer registry linkage allowed for the greatest and most accurate follow-up time
possible for each of the ABOi kidney transplant recipients captured; however, because the
practice of ABOi transplantation is a relatively recent one, our median follow-up time could
only be 2 years. It is possible that differences in cancer risk will become apparent when
increasing numbers of ABOi recipients are followed for longer periods of time. While our
cohort is the largest to date in answering this question, it is nonetheless too small to allow
additional interesting analyses such as stratification by blood type, other recipient
characteristics, or cancer types. Limitations also include lack of antibody titer in SRTR data,
minimal information about desensitization protocols, and likely heterogeneity in practice
patterns throughout the country. Another limitation is the lack of information on the
incidence of non-melanoma skin cancer, the most common cancer after transplantation.
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Expansion of ABOi kidney transplantation offers hope for increasing available kidney
donors and access to transplantation. As outcomes after ABOi transplantation improve, it
will be necessary to closely study the possible long-term risks associated with this
procedure. Using the largest, albeit not large, national cohort to date, we were unable to
demonstrate differences in cancer risk associated with ABOi compared with ABOc kidney
transplantation. Further efforts should be made to capture accurate information on additional
incompatible transplants and to track the long-term outcomes in this unique cohort of
recipients.
Methods
Eligible living kidney recipients were identified in the TCM Study, a linkage of data from
SRTR (1987–2008) with 14 population-based cancer registries throughout the United States
(http://transplantmatch.cancer.gov/). The SRTR includes data on all U.S. solid organ
transplants. Participating cancer registries, which together cover approximately 43% of the
U.S. transplant population, ascertained the occurrence of malignancies (other than basal cell
and squamous cell skin cancer) based on mandatory reporting from hospitals, medical
providers, and pathology laboratories. Following linkage with the SRTR, investigators
retained only anonymized data from the cancer registries. The study was approved by
human subjects committees at the National Cancer Institute and, as required, at participating
cancer registries.
Eligible recipients were those that received an ABOi living donor kidney transplant during a
time period with available data on cancer from participating registries. We used the linked
cancer registry data to identify first incident cancer cases following transplantation. Cancers
were classified and recorded by cancer registries using topography and morphology codes.
Follow-up started at transplantation and ended at death, graft failure, retransplantation, loss
of follow-up, or end of cancer registry coverage.
Unadjusted incidence rate ratios and exact 95% confidence intervals for ABOi vs. ABO
compatible (ABOc) living donor kidney recipients were calculated for all cancers and
separately for non-Hodgkin lymphoma (NHL). In addition, a matched control cohort was
created by matching ABOc living kidney recipients 5-to-1 with ABOi recipients. Matches
were drawn from 37,643 possible ABOc controls available in SRTR data. Using iterative
expanding radius matching as previously described [28, 29], each control was matched on
age at transplantation, gender, race, zero HLA mismatch status, retransplantation, and year
of transplant. Based on an incidence rate of 0.0085 per year in the ABOc cohort, we had
80% power to detect a 3-fold increase in cancer incidence based on our cohort of 318 ABOi
patients.
All analyses were performed using Stata 12.0/MP for Linux (StataCorp, College Station,
TX, www.stata.com).
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Table 1









  0–35 107 (33.7) 13,669 (36.3) 550 (34.6)
  36–50 99 (31.1) 12,392 (32.9) 467 (29.2)
  51–60 70 (22.0) 7,357 (19.5) 374 (23.5)
  >60 42 (13.2) 4,225 (11.2) 199 (12.5)
Gender 0.5
  Male 181 (56.9) 22,067 (58.6) 905 (56.9)
  Female 137 (43.1) 15,576 (41.4) 685 (43.1)
Raceb 0.02
  White 190 (60.1) 23,208 (62.1) 954 (60.0)
  African-American 61 (19.0) 5,238 (14.0) 307 (19.3)
  Hispanic/Other 65 (20.6) 8,941 (23.9) 329 (20.7)
Zero HLA Mismatchb 0.6
  No 274 (88.7) 32,377 (87.6) 1,410 (88.7)
  Yes 35 (11.3) 4,575 (12.4) 180 (11.3)
Retransplantation 0.03
  No 282 (88.7) 34,633 (92.0) 1,410 (88.7)
  Yes 36 (11.3) 3,010 (8.00) 180 (11.3)
ABOi = ABO incompatible; ABOc = ABO compatible. Cells show N (%).
a)
Matched 5 to 1 on age at transplantation (within five years), gender, race, zero HLA mismatch status, retransplantation, and year of transplant
(within ten years) to ABOi recipients.
b)
Recipients do not sum to total because of missing data. P-values represent the comparison between ABOi patients and the entire ABOc cohort,
using a chi-squared test.
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Table 3
Cancer risk after living donor kidney transplantation, comparing ABO incompatible recipients with ABO






  Rateb 7.1 8.5 7.1
  IRR (95% CI) vs. entire cohort 0.86 (0.02–4.85) Reference
  IRR (95% CI) vs. matched controls 0.99 (0.38–2.23) Reference
NHL
  Rateb 1.0 1.2 1.0
  IRR (95% CI) vs. entire cohort 0.76 (0.02–4.29) Reference
  IRR (95% CI) vs. matched controls 1.02 (0.02–8.38) Reference
ABOi = ABO incompatible; ABOc = ABO compatible; IRR = incidence rate ratio; CI = confidence interval; NHL = non-Hodgkin lymphoma.
a)
Matched 5 to 1 on age at transplantation, gender, race, zero HLA mismatch status, retransplantation, and year of transplant to ABOi recipients.
b)
Per 1,000 person-years
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